qa:qa_dcx-login
Xpert® Xpress CoV-2 plus
Designed with 3 gene targets for a rapid, robust detection of SARS-CoV-2
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
XP3SARS-COV2-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Copan 305CN (Nasopharyngeal Swab) (Pack of 50)
305C
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Copan 346N (Nasal Swab) (Pack of 50)
346C
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Nasal Collection Kit (Pack of 100)
SWAB/F-100
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
- Rapidly detect SARS-CoV-2, including emerging variants, to provide timely, effective triage
- Increase workflow efficiencies with minimal hands-on time
Test
The Solution
The Xpert Xpress CoV-2 plus test provides:
- Fast and accurate results in as early as 20 minutes*
- Three gene targets for SARS-CoV-2 as well as an optimization of SARS-CoV-2 probes to enable more realizable virus detection
- Rapid sample-to-answer testing with actionable results from a single sample
*With early assay termination for positives, otherwise, the full test runtime is 30 minutes.
The Impact
- Offers healthcare providers lab-quality results in a test that can be performed at the point of care
- Supports clinicians with broader coverage for SARS-CoV-2 variants with a three-gene design
- Enables hospitals to effectively manage limited resources with our single-cartridge technology and easy-to-use workflow
In the United States: This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries